Biophytis (EPA:ALBPS)

REGULATED PRESS RELEASE

published on 09/30/2024 at 23:00, 1 year 5 months ago

Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities
Biophytis publishes first-half financial results and updates on business activities, highlighting key achievements including launch of OBA program for obesity with BIO101 and exclusive licensing agreement with Blanver for Latin America

Financial Results Biophytis Latin America BIO101 OBA Program
BRIEF

published on 07/22/2024 at 08:17, 1 year 8 months ago

Biophytis Enters Asia Market with Strategic Partnerships

Biophytis Pharmaceutical Partnerships Market Expansion Asia
PRESS RELEASE

published on 07/22/2024 at 08:12, 1 year 8 months ago

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia
Biophytis signs partnership contracts with local agents in Asia to accelerate deployment of BIO101 drug candidate, targeting age-related diseases in key markets like Japan and China

Biophytis Partnership Asia Age-related Diseases BIO101
BRIEF

published on 07/22/2024 at 07:05, 1 year 8 months ago

Biophytis Signs Contracts with Local Agents in Asia

Biotechnology Pharmaceutical Partnerships Age-related Diseases Asia Market
REGULATED PRESS RELEASE

published on 07/22/2024 at 07:00, 1 year 8 months ago

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia
Biophytis implements partnership strategy in Asia with new contracts to advance drug candidate BIO101 in Japan, South Korea, China, and Southeast Asia

Biophytis Asia Contracts Partnership Strategy Drug Candidate BIO101
BRIEF

published on 07/11/2024 at 08:18, 1 year 8 months ago

Biophytis Obtains IND Approval from FDA for Phase 2 Obesity Study

Biophytis FDA Approval Phase 2 Clinical Trial BIO101 Obesity Study
PRESS RELEASE

published on 07/11/2024 at 08:13, 1 year 8 months ago

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
Biophytis receives FDA IND approval for phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by renowned expert Marc-André Cornier

FDA Biophytis Obesity IND Approval OBA Study
BRIEF

published on 07/11/2024 at 07:06, 1 year 8 months ago

Biophytis Receives FDA IND Approval for Phase 2 Obesity Study

Biophytis FDA Approval Phase 2 Study BIO101 Obesity
REGULATED PRESS RELEASE

published on 07/11/2024 at 07:01, 1 year 8 months ago

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
Biophytis obtains FDA approval to start phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by Prof. Marc-André Cornier to start mid-2024 in the USA

Biophytis FDA Approval Obesity Treatment BIO101 Phase 2 OBA Study
BRIEF

published on 07/01/2024 at 07:05, 1 year 8 months ago

Biophytis Presents Promising Phase 2-3 COVA Study Results on Severe Covid-19 at WCID in Paris

Biophytis COVID-19 Clinical Trials COVA Study Infectious Diseases

Published on 03/20/2026 at 23:00, 2 days 1 hour ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 2 days 2 hours ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 2 days 2 hours ago

Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 2 days 10 hours ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 11 hours ago

CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals

View all ACCESSWIRE

Published on 03/22/2026 at 18:22, 5 hours 47 minutes ago

Test news - please ignore EN
Published on 03/22/2026 at 12:23, 11 hours 46 minutes ago

Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 2 days 1 hour ago

Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 2 days 3 hours ago

Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 2 days 3 hours ago

Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion

View all EQS

Published on 03/20/2026 at 19:00, 2 days 5 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 2 days 5 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 17:45, 2 days 6 hours ago

Cie du Bois Sauvage : Annual report 2025
Published on 03/20/2026 at 16:57, 2 days 7 hours ago

Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 3 days 6 hours ago

Filing of the 2025 Universal Registration Document

View all LES ECHOS COMFI WIRE

News